The Seraseq® ctDNA MRD Mix Kit is now available as individually orderable vials at individual tumor fractions (0%, 0.5%, 0.05%, 0.005%). You can now purchase the specific tumor fractions you need, making it more convenient to tailor your assays and experiments.
Learn more about our product!
Want to request pricing or get expert guidance? Fill out the form and an expert will follow up with everything you need promptly.
MRD monitoring helps track cancer progression and guide treatment decisions. Liquid biopsy (ctDNA) enables less invasive monitoring by detecting tumor-specific variants in blood. Assay developers need reliable, ground-truth materials to validate and standardize these tests.
Our solution
The Seraseq ctDNA MRD Mix combines cancerous and matched normal cell line DNA with synthetic DNA containing therapeutic mutations, enabling reliable detection of low levels of cancer DNA in blood. DNA is fragmented to mimic ctDNA and blended at four tumor fractions: 0%, 0.5%, 0.05%, and 0.005%.
Key features
-
Highly multiplexed variants across solid tumor genes (AKT1, BRCA1/2, EGFR, KRAS, NRAS, PIK3CA, ERBB2 and more)
-
Ready-to-use, purified DNA mix for targeted sequencing workflows
-
Consistent ground truth for assay development, validation, and routine monitoring
-
Manufactured in GMP-compliant, ISO 13485-certified facilities
Individual Vials:
- Seraseq ctDNA MRD 0% Tumor: 0710-3670
- Seraseq ctDNA MRD 0.5% Tumor: 0710-3671
- Seraseq ctDNA MRD 0.05% Tumor: 0710-3672
- Seraseq ctDNA MRD 0.005% Tumor: 0710-367
Kit:
- Seraseq ctDNA MRD Mix: 0710-2146
(Kit contains 4 vials: 0%, 0.5%, 0.05% & 0.005% tumor fractions)
Access the complete list of mutations in Seraseq ctDNA MRD Mix.